Sarepta Therapeutics,, Inc. Common Stock

In the latest quarter, 14 analysts provided ratings for Sarepta Therapeutics (NASDAQ:SRPT), showcasing a mix of bullish and bearish perspectives. The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 6 3 5 0 0 Last 30D 1 0 1 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 5 3 4 0 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $157.21, with a high estimate of $224.00 and a low estimate of $128.00. Observing a 8.14% increase, the current average has risen from the previous average price target of $145.38. Deciphering Analyst Ratings: An In-Depth Analysis An in-depth analysis of recent analyst actions unveils how financial experts perceive Sarepta Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Kristen Kluska Cantor Fitzgerald Maintains Neutral $128.00 - Gil Blum Needham Maintains Buy $166.00 - Colin Bristow UBS Raises Buy $167.00 $164.00 Kristen Kluska Cantor Fitzgerald Maintains Neutral $128.00 - Brian Abrahams RBC Capital Raises Outperform $157.00 $151.00 David Hoang Citigroup Raises Buy $172.00 $160.00 Gena Wang Barclays Raises Overweight $185.00 $141.00 Gil Blum Needham Lowers Buy $166.00 $169.00 Gavin Clark-Gartner Evercore ISI Group Raises In-Line $138.00 $108.00 Andreas Argyrides Wedbush Maintains Outperform $224.00 - Gil Blum Needham Raises Buy $169.00 $140.00 Kristen Kluska Cantor Fitzgerald Maintains Neutral $128.00 - Uy Ear Mizuho Raises Buy $145.00 $130.00 Kristen Kluska Cantor Fitzgerald Maintains Neutral $128.00 - Key Insights: Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their ...Full story available on Benzinga.com

Related tickers: SRPT.

Sarepta (SRPT) reports better-than-expected Q1 earnings on the back of strong sales for recently-approved DMD gene therapy Elevidys.

Related tickers: RHHBY, LGND, SRPT, ANIP.